NeurologyLive® Mind Moments®

152: Building Safer, Smarter, and More Personalized Epilepsy Care


Listen Later

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Building Safer, Smarter, and More Personalized Epilepsy Care," Orrin Devinsky, MD, discusses major areas of progress and ongoing challenges in epilepsy care. Devinsky, a professor in the departments of neurology, neurosurgery, and psychiatry at NYU Grossman School of Medicine, reflects on how the treatment landscape has evolved in recent years, including advances in medication, awareness of SUDEP, and patient counseling. Devinsky also weighs in on the current treatment hierarchy for antiepileptic drugs and whether first-line therapeutic strategies should change. Additional discussion touches on the state of gene therapy development, the need for greater research in disease prevention, the implications of GLP/GIP agents in neurological care, and how neurodevelopmental management is advancing for pediatric patients with epilepsy.

Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:
  • 0:55 – How epilepsy care has evolved and where progress has been made
  • 5:30 – Whether first-line therapy choices for epilepsy should be re-evaluated
  • 8:35 – Why gene therapy progress has been slower than expected in epilepsy
  • 12:05 – Neurology News Minute
  • 14:10 – What areas of epilepsy research deserve greater attention and funding
  • 17:10 – How GLP/GIP agents could intersect with neurological and epilepsy care
  • 20:00 – How clinicians can better address neurodevelopmental challenges in patients with epilepsy

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Neflamapimod Advances to Phase 3 Trial in Dementia With Lewy Bodies After Positive RewinD-LB Results
    • FDA Delays Review Deadline for Hunter Syndrome Agent Tividenofusp Alfa
    • FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology

    • Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
      ...more
      View all episodesView all episodes
      Download on the App Store

      NeurologyLive® Mind Moments®By NeurologyLive

      • 4.6
      • 4.6
      • 4.6
      • 4.6
      • 4.6

      4.6

      10 ratings


      More shows like NeurologyLive® Mind Moments®

      View all
      NEJM This Week by NEJM Group

      NEJM This Week

      321 Listeners

      Neurology® Podcast by American Academy of Neurology

      Neurology® Podcast

      302 Listeners

      Practical Neurology Podcast by BMJ Group

      Practical Neurology Podcast

      49 Listeners

      The Clark Howard Podcast by Clark Howard

      The Clark Howard Podcast

      5,457 Listeners

      JAMA Neurology Author Interviews by JAMA Network

      JAMA Neurology Author Interviews

      12 Listeners

      BMJ Best Practice Podcast by BMJ Group

      BMJ Best Practice Podcast

      21 Listeners

      Neurology Today in 5 by American Academy of Neurology

      Neurology Today in 5

      25 Listeners

      Neurology Minute by American Academy of Neurology

      Neurology Minute

      133 Listeners

      Dateline NBC by NBC News

      Dateline NBC

      47,622 Listeners

      The Ezra Klein Show by New York Times Opinion

      The Ezra Klein Show

      16,096 Listeners

      Movers and Shakers: a podcast about life with Parkinson's by Podot

      Movers and Shakers: a podcast about life with Parkinson's

      106 Listeners

      Continuum Audio by American Academy of Neurology

      Continuum Audio

      80 Listeners

      Chanticleer by Australian Financial Review

      Chanticleer

      21 Listeners

      The Top Line by Fierce Life Sciences

      The Top Line

      13 Listeners

      The Economics Show by Financial Times

      The Economics Show

      140 Listeners